Becky Kamowitz was named executive director of the Skin Cancer Foundation, a national nonprofit organization that is committed to decreasing the incidence and mortality skin cancer through public education. Kamowitz has worked for the foundation for more than a decade and previously served as interim executive director and senior director of marketing communications.
FDA approved Unloxcyt (osibelimab-ipdl), a programmed death ligand-1 blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
